Drug Profile
4-antigen Staphylococcus aureus vaccine - Pfizer
Alternative Names: PF-06290510; PF-6290510; Quadrivan; SA4AgLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Pfizer
- Class Bacterial vaccines; Conjugate vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Staphylococcal infections
Most Recent Events
- 20 Dec 2018 Pfizer terminates the phase II STRIVE trial in Staphylococcal infections in US, Canada, France, Germany, Spain, Sweden, Hungary, Bulgaria, Austria and the UK
- 21 Apr 2018 Immunogenicity and safety data from a phase II trial in Staphylococcal infections presented at the 28th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID-2018)
- 01 Sep 2016 Pfizer completes a phase II trial in Staphylococcal infections (Prevention) in Japan (IM) (NCT02492958)